2. Search Result
Search Result
Results for "

DMBA

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W011845
    DMBA

    7,12-DMBA; 7,12-Dimethylbenzanthracene

    		 Others Cancer
    DMBA has carcinogenic activity as a polycyclic aromatic hydrocarbon (PAH). DMBA is used to induce tumor formation in various rodent models .
    DMBA
  • HY-126573
    Trilaurin

    		Endogenous Metabolite Cancer
    Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .
    Trilaurin
  • HY-W543743
    1-Ethenylpyrene

    1-Vinylpyrene

    		 Others Cancer
    1-Ethenylpyrene (1-Vinylpyrene) is an anti-chemical carcinogen that inhibits the formation of skin tumors initiated by either DMBA (HY-W011845) or Benzo[a]pyrene (HY-107377) .
    1-Ethenylpyrene
  • HY-N0679
    Retinyl acetate
    2 Publications Verification

    Retinol acetate; Vitamin A acetate

    		 Others Cancer
    Retinyl acetate is a synthetic acetate ester form derived from retinol and has potential antineoplastic and chemo preventive activities .
    Retinyl acetate
  • HY-160702
    DMBA-SIL-Mal-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    DMBA-SIL-Mal-MMAE is a cytotoxin-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked DMBA-SIL-Mal .
    DMBA-SIL-Mal-MMAE
  • HY-160703
    DMBA-SIL-PNP

    		Others Cancer
    DMBA-SIL-PNP (Compound 5) is an intermediate used for preparing Drug-Linker Conjugates, which can be applied in cancer research .
    DMBA-SIL-PNP
  • HY-126573R
    Trilaurin (Standard)

    		Others Cancer
    Trilaurin (Standard) is the analytical standard of Trilaurin. This product is intended for research and analytical applications. Trilaurin could inhibit the formation of neoplasms initiated by dimethylbenzanthracene (DMBA) and promoted by croton oil .
    Trilaurin (Standard)
  • HY-N0679R
    Retinyl acetate (Standard)

    		Others Cancer
    Retinyl acetate (Standard) is the analytical standard of Retinyl acetate. This product is intended for research and analytical applications. Retinyl acetate is a synthetic acetate ester form derived from retinol and has potential antineoplastic and chemo preventive activities .
    Retinyl acetate (Standard)
  • HY-19590
    Etarotene

    Ro 15-1570

    		 Others Cancer
    Etarotene (Ro 15-1570) is a derivative of Arotinoid (HY-106735). Etarotene is an orally active antitumor agent against DMBA (HY-W011845)-induced mammary tumor and causes toxic symptoms of hypervitaminosis A in rat model .
    Etarotene
  • HY-124403
    D 15413

    		Estrogen Receptor/ERR Cancer
    D 15413 is an orally active antagonist for nonsteroidal estrogen. D 15413 inhibits growth of estrogen receptor positive MCF-7 cell with an inhibition rate of 70% at 10 -7 M. D 15413 exhibits antitumor efficacy against DMBA (HY-W011845) or MNU (HY-34758)-induced breast cancer .
    D 15413
  • HY-16290
    Lonaprisan

    ZK 230211; BAY86 5044

    		 Progesterone Receptor Endocrinology
    Lonaprisan (ZK 230211; BAY86 5044) is an antagonist for progesterone receptor, with IC50 of 3.6 pM and 2.5 pM for PR-A and PR-B, respectively. Lonaprisan exhibits antiprogestagenic activity in rabbits, interrupts early pregnancy in rats, and exhibits antitumor efficacy against DMBA (HY-W011845)-induced mammary tumor. Lonaprisan reveals antiglucocorticoid and antiandrogenic effect .
    Lonaprisan
  • HY-110002
    LFM-A13
    1 Publications Verification

    		 Polo-like Kinase (PLK) Btk JAK Cancer
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research
    LFM-A13
  • HY-114631
    EM-800

    		Estrogen Receptor/ERR Cancer
    EM-800, an orally active anti-estrogen, serves as an antagonist to the transcriptional functions of estrogen receptors α (ERα) and β (ERβ). EM-800 possesses anticancer activity, capable of inhibiting the growth of breast cancer induced by 7,12-Dimethylbenz[a]anthracene (DMBA) (HY-W011845). Furthermore, in ovariectomized animals, EM-800 effectively slows down bone loss. Additionally, EM-800 shows potential in the research of breast and endometrial cancers, while exerting beneficial effects on bone and lipid metabolism .
    EM-800

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: